<SEC-DOCUMENT>0001683168-21-003371.txt : 20210810
<SEC-HEADER>0001683168-21-003371.hdr.sgml : 20210810
<ACCEPTANCE-DATETIME>20210809201856
ACCESSION NUMBER:		0001683168-21-003371
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20210809
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210810
DATE AS OF CHANGE:		20210809

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RadNet, Inc.
		CENTRAL INDEX KEY:			0000790526
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				133326724
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33307
		FILM NUMBER:		211158053

	BUSINESS ADDRESS:	
		STREET 1:		1510 COTNER AVE
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90025
		BUSINESS PHONE:		3104787808

	MAIL ADDRESS:	
		STREET 1:		1510 COTNER AVE
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRIMEDEX HEALTH SYSTEMS INC
		DATE OF NAME CHANGE:	19930518

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CCC FRANCHISING CORP
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>radnet_i8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:RDNT="http://radnet.com/20210809">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_036_RDNT_radnet.com_20210809 -->
<!-- Field: Set; Name: xdx; ID: xdx_04E_20210809_20210809 -->
<!-- Field: Set; Name: xdx; ID: xdx_05C_edei%2D%2DEntityCentralIndexKey_0000790526 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-08-09to2021-08-09" name="dei:EntityCentralIndexKey">0000790526</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-08-09to2021-08-09" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="rdnt-20210809.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-08-09to2021-08-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000790526</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-09</xbrli:startDate>
        <xbrli:endDate>2021-08-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">UNITED STATES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES AND EXCHANGE
COMMISSION</b></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Washington, D.C. 20549</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 14pt"><b>FORM
<span id="xdx_90E_edei--DocumentType_c20210809__20210809_z1md0eCsLgm5"><ix:nonNumeric contextRef="From2021-08-09to2021-08-09" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of
earliest event reported): <span id="xdx_908_edei--DocumentPeriodEndDate_c20210809__20210809_zs0sYdhFQcJb"><ix:nonNumeric contextRef="From2021-08-09to2021-08-09" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">August 9, 2021</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">_______________________________________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span id="xdx_903_edei--EntityRegistrantName_c20210809__20210809_z0qbjFDTuSK8"><ix:nonNumeric contextRef="From2021-08-09to2021-08-09" name="dei:EntityRegistrantName">RadNet, Inc.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant
as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<hr style="border-width: 0; color: Gray; background-color: Gray; height: 1px; width: 100%; margin-top: 3pt; margin-bottom: 3pt" />
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="text-align: center; padding-left: 10pt; width: 33%"><span id="xdx_909_edei--EntityIncorporationStateCountryCode_c20210809__20210809_zrprZrq8xbol"><ix:nonNumeric contextRef="From2021-08-09to2021-08-09" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></td>
    <td style="text-align: center; padding-left: 10pt; width: 34%"><span id="xdx_903_edei--EntityFileNumber_c20210809__20210809_zILAq92GyNJc"><ix:nonNumeric contextRef="From2021-08-09to2021-08-09" name="dei:EntityFileNumber">001-33307</ix:nonNumeric></span></td>
    <td style="text-align: center; width: 33%"><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20210809__20210809_zaq0OEtWkAF6"><ix:nonNumeric contextRef="From2021-08-09to2021-08-09" name="dei:EntityTaxIdentificationNumber">13-3326724</ix:nonNumeric></span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; padding-left: 10pt">(State or other jurisdiction
of incorporation)</td>
    <td style="text-align: center; padding-left: 10pt">(Commission File Number)</td>
    <td style="text-align: center">(IRS
Employer Identification Number)</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.9pt; text-indent: -16.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_905_edei--EntityAddressAddressLine1_c20210809__20210809_zWHCojd4huF7"><ix:nonNumeric contextRef="From2021-08-09to2021-08-09" name="dei:EntityAddressAddressLine1">1510 Cotner Avenue</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_90E_edei--EntityAddressCityOrTown_c20210809__20210809_zG8Lf5Uedggh"><ix:nonNumeric contextRef="From2021-08-09to2021-08-09" name="dei:EntityAddressCityOrTown">Los Angeles</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressStateOrProvince_c20210809__20210809_zhU0ZbhmM35k"><ix:nonNumeric contextRef="From2021-08-09to2021-08-09" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span>
<span id="xdx_907_edei--EntityAddressPostalZipCode_c20210809__20210809_zCoOwEKSej8b"><ix:nonNumeric contextRef="From2021-08-09to2021-08-09" name="dei:EntityAddressPostalZipCode">90025</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of Principal Executive
Offices) (Zip Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_90F_edei--CityAreaCode_c20210809__20210809_zFQ9QsxG0Sjj"><ix:nonNumeric contextRef="From2021-08-09to2021-08-09" name="dei:CityAreaCode">(310)</ix:nonNumeric></span> <span id="xdx_908_edei--LocalPhoneNumber_c20210809__20210809_zpevIDX050a9"><ix:nonNumeric contextRef="From2021-08-09to2021-08-09" name="dei:LocalPhoneNumber">445-2800</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Registrant&#8217;s Telephone
Number, Including Area Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 5.7pt"></td><td style="width: 21.5pt"><span style="font-family: Wingdings"><span id="xdx_902_edei--WrittenCommunications_c20210809__20210809_zKCwrS3pyEx2"><ix:nonNumeric contextRef="From2021-08-09to2021-08-09" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td><td>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 5.7pt"></td><td style="width: 21.5pt"><span style="font-family: Wingdings"><span id="xdx_90B_edei--SolicitingMaterial_c20210809__20210809_zLRO2vd1jAwj"><ix:nonNumeric contextRef="From2021-08-09to2021-08-09" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td><td>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 5.7pt"></td><td style="width: 21.5pt"><span style="font-family: Wingdings"><span id="xdx_906_edei--PreCommencementTenderOffer_c20210809__20210809_zytGgOLcxRD9"><ix:nonNumeric contextRef="From2021-08-09to2021-08-09" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td><td>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 5.7pt"></td><td style="width: 21.5pt"><span style="font-family: Wingdings"><span id="xdx_90B_edei--PreCommencementIssuerTenderOffer_c20210809__20210809_zi4Sn5Clzxz"><ix:nonNumeric contextRef="From2021-08-09to2021-08-09" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td><td>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Securities registered pursuant to Section
12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center; width: 33%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Title of Each Class</span></span></td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center; width: 34%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Trading Symbol(s)</span></span></td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center; width: 33%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Name of each exchange on which registered</span></span></td></tr>
<tr>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_edei--Security12bTitle_c20210809__20210809_zJMrRqo3NCCb"><ix:nonNumeric contextRef="From2021-08-09to2021-08-09" name="dei:Security12bTitle">Common Stock, $.0001 par value</ix:nonNumeric></span></span></td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_edei--TradingSymbol_c20210809__20210809_zL5zq5trQsma"><ix:nonNumeric contextRef="From2021-08-09to2021-08-09" name="dei:TradingSymbol">RDNT</ix:nonNumeric></span></span></td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_edei--SecurityExchangeName_c20210809__20210809_zG2v1o6PfFb1"><ix:nonNumeric contextRef="From2021-08-09to2021-08-09" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ Global Market</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">Emerging
growth company&#160;&#160;&#160;</span><span style="font-family: Wingdings"><span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20210809__20210809_zjRYAxXvf69d"><ix:nonNumeric contextRef="From2021-08-09to2021-08-09" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;
</span><span style="font-family: Wingdings">&#168;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in">Item 2.02</td><td>RESULTS OF OPERATIONS AND FINANCIAL CONDITION</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 9, 2021 RadNet,
Inc. (&#8220;RadNet&#8221;) issued a press release and held a conference call regarding our 2021 financial results for the second quarter
ended June 30, 2021. A copy of the press release is furnished as Exhibit 99.1 and a copy of the transcript of the conference call is furnished
as Exhibit 99.2 to this Current Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information in this Current
Report, including Exhibit 99.1 and Exhibit 99.2 is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section
18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Current Report,
including Exhibit 99.1 and Exhibit 99.2 shall not be incorporated by reference into any registration statement or other document filed
with the Commission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b>Item 9.01</b></td><td style="text-align: justify"><b>FINANCIAL STATEMENTS AND EXHIBITS.</b></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 15%"><span style="text-decoration: underline">Exhibit Number</span></td>
  <td style="width: 85%"><span style="text-decoration: underline">Description of Exhibit</span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>99.1</td>
  <td><a href="radnet_ex9901.htm">Press Release dated August 9, 2021 relating to RadNet, Inc.&#8217;s financial results for the quarter ended June 30, 2021.</a></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>99.2</td>
  <td><a href="radnet_ex9902.htm">Transcript of conference call.</a></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td></tr>

<tr style="vertical-align: top; text-align: left">
  <td>104</td>
  <td>Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal"></span></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">SIGNATURE</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 50%">Date:&#160;&#160;&#160;August 9, 2021</td>
    <td style="text-align: left; width: 50%"><b>RADNET, INC.</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left">
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">By: <span style="text-decoration: underline">/s/ Mark D. Stolper </span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Name: Mark D. Stolper<br />
    Title: Chief Financial Officer</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in">&#160;</p></td></tr>
  </table>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT INDEX</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 15%"><span style="text-decoration: underline">Exhibit Number</span></td>
  <td style="width: 85%"><span style="text-decoration: underline">Description of Exhibit</span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>99.1</td>
  <td><a href="radnet_ex9901.htm">Press Release dated August 9, 2021</a></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>99.2</td>
  <td><a href="radnet_ex9902.htm">Transcript of conference call.</a></td></tr>
</table>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal"></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6LdpNBbdLh4o4ZYwh3hYXpbg1I61/j+Rb2m2IIRCSc74cIUZiQ2tdI8NpWWRQYtPWyiEUeEFGc0bvSLe7BPws8KqtY2Vcv/7AlDyDnpmPY+XvvfOhLVYJyMVExpMoBDlL5BTyvQg6PSVz0RUap1UNylSQM7Ws0Sl+Dx9K9SJDzbtPOiJbTSaBcCwH+QORDCM40EM9iW8WsiwVwaivQGyY7m0Xc7eOGljV2PgsO6D/Dr7iWkkg -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>radnet_ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 99.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: red"><B><IMG SRC="image_002.jpg" ALT="RadNet Logo JPEG  - no tag line" STYLE="height: 99px; width: 230px"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOR IMMEDIATE RELEASE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Revenue increased 75.2% to an all-time quarterly record of $333.9 million
in the second quarter of 2021 from $190.6 million in the second quarter of 2020</I></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Adjusted EBITDA<SUP>(1)</SUP> increased 150.7% to an all-time quarterly
record of $56.6 million in the second quarter of 2021 from $22.6 million in the second quarter of 2020</I></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Adjusting for one-time items impacting Net Income in the quarter, Adjusted
Earnings Per Share<SUP>(3)</SUP> was $0.27 for the second quarter of 2021; This compares with Adjusted Net Loss<SUP>(3)</SUP> of $(0.14)
per diluted share for the second quarter of 2020 </I></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Aggregate procedural volumes increased 92.7%; Same-center procedural volumes
increased 80.5% compared to the second quarter of 2020</I></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>RadNet has completed deployment of its FDA approved DeepHealth Saige-Q<SUP>TM</SUP>
mammography AI software within its northeast and mid-Atlantic centers with positive physician reception</I></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>RadNet further revises full-year 2021 guidance levels to increase Revenue,
Adjusted EBITDA<SUP>(1)</SUP> and Free Cash Flow ranges</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>LOS ANGELES, California, August 9, 2021 &ndash;
RadNet, Inc. (NASDAQ: RDNT),</B> <FONT STYLE="color: black">a national leader in providing high-quality, cost-effective, fixed-site outpatient
diagnostic imaging services through a network of 353 owned and/or operated outpatient imaging centers</FONT>, today reported financial
results for its second quarter of 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Howard Berger, President and Chief Executive
Officer of RadNet, commented, &ldquo;I am extremely pleased with our financial results in the second quarter. We set all-time quarterly
records for Revenue and Adjusted EBITDA<SUP>(1)</SUP>, and achieved an Adjusted EBITDA<SUP>(1)</SUP> margin of 17.0%, higher by 5.1% and
2.1% from the second quarters of 2020 and 2019, respectively. The strong operating performance was the result of recovering procedural
volumes in combination with lower costs as a result of actions we took during the COVID-19 period in 2020 and continued cost-containment
measures implemented in 2021. Additionally, improvements in our revenue cycle and cash collections have contributed to our improving results
and lower DSOs. We are seeing opportunity in virtually all aspects of our multi-faceted business. We project significant growth ahead
from the strategic capital investments we are making in equipment, our development efforts in artificial intelligence, the pipeline for
tuck-in acquisitions and discussions surrounding new hospital health system joint ventures.&rdquo;</P>

<P STYLE="color: red; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Berger continued, &ldquo;Given the positive
trends we are experiencing in our business and the strong financial performance of both the first and second quarters, we have elected
to further revise our guidance levels upwards. The increased 2021 guidance ranges for Revenue, Adjusted EBITDA<SUP>(1)</SUP> and Free
Cash Flow also anticipate improved operating margins. While our revised guidance is reflective of our confidence and optimism regarding
the rest of the year&rsquo;s performance, we remain cognizant of the possibility of an additional surge of COVID-19 or its Delta variant
in any or all of our regional markets, and are prepared to respond appropriately,&rdquo; added Dr. Berger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Berger concluded, &ldquo;On April 19<SUP>th</SUP>,
we announced that we received FDA clearance for our DeepHealth AI mammography triage software, Saige-Q<SUP>TM</SUP>, which is a worklist
prioritization tool that enables radiologists to more effectively manage their mammography cases with the use of artificial intelligence.
We are in the process of deploying this technology across our various markets and are pleased to announce that we have completed installation
of this technology in our northeast and mid-Atlantic markets. We expect to complete nationwide deployment, to include our radiologists
in California, by the end of the third quarter. Early feedback from our radiologists is excellent. While we are observing improved productivity,
most importantly, we are providing our patients and payors with greater accuracy, fewer patient call-backs and the possibility of detecting
breast disease one to two years earlier than otherwise possible. We continue to evaluate further areas of AI that can improve effectiveness,
decrease costs and drive new revenue streams through providing innovative cost effective screening programs to large insurance companies
who are interested in new population health models to improve patient care.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Second Quarter Financial Results</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the second quarter of 2021, RadNet reported
Revenue of $333.9 million and Adjusted EBITDA<SUP>(1)</SUP> of $56.6 million. Revenue increased $143.4 million (or 75.2%) and Adjusted
EBITDA<SUP>(1)</SUP> increased $34.0 million (or 150.7%) from the second quarter of 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adjusted Diluted Net Income Attributable to RadNet,
Inc. Common Stockholders (Adjusted Earnings<SUP>(3)</SUP>) for the second quarter of 2021 was $14.2 million, or $0.27 per diluted share
as compared with Adjusted Net Loss of $6.9 million, or $(0.14) per diluted share for the same period in 2020. Unadjusted for one-time
items, Net Income Attributable to RadNet, Inc. Common Shareholders (&ldquo;Net Income&rdquo;) for the second quarter of 2021 was $2.9
million, or $0.05 per diluted share. This compares to Net Loss of $10.6 million, or $(0.21) per diluted share, in the second quarter of
2020. These per share values are based upon weighted average number of diluted shares outstanding of 53.1 million in the second quarter
of 2021 and 50.7 million of diluted shares outstanding in the second quarter of 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">Affecting Net Income
in the second quarter of 2021 were certain non-cash expenses and non-recurring items including: $---8.9 million of non-cash employee stock
compensation expense; $268,000 of severance paid in connection with headcount reductions related to cost savings initiatives; $1.6 million
gain on the disposal of certain capital equipment; </FONT>$1.2 million of non-cash loss from interest rate swaps; $6.0 million expense
from debt restructuring and extinguishment as a result of our recent refinancing transaction; <FONT STYLE="color: black">and $812,000
of amortization of deferred financing costs and loan discount related to our existing credit facilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the second quarter of 2021, as compared with
the prior year&rsquo;s second quarter, MRI volume increased 88.1%, CT volume increased 67.6% and PET/CT volume increased 28.8%. Overall
volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 92.7% over the
prior year&rsquo;s second quarter. On a same-center basis, including only those centers which were part of RadNet for both the second
quarters of 2021 and 2020, MRI volume increased 73.0%, CT volume increased 54.9% and PET/CT volume increased 26.5%. Overall same-center
volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 80.5% from the
prior year&rsquo;s same quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Six Month Financial Results</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the six months ended June 30, 2021, RadNet
reported Revenue of $649.2 million and Adjusted EBITDA<SUP>(1)</SUP> of $102.1 million. Revenue increased $177.1 million (or 37.5%) and
Adjusted EBITDA<SUP>(1)</SUP> increased $59.2 million (or 137.8%) from the same six month period last year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the six month period in 2021, RadNet reported
Net Income of $12.3 million, an increase of approximately $39.3 million over the first six months of 2020. Per share diluted <FONT STYLE="color: black">Net
Income for the first six months of 2021 was $0.23, compared to a diluted Net Loss of $(0.53) in the same six month period of 2020 (based
upon a weighted average number of diluted shares outstanding of 52.9 million in 2021 and 50.5 million in 2020).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">Affecting Net Income
for the six month period of 2021 were certain non-cash expenses and non-recurring items including: $17.1 million of non-cash employee
stock compensation expense; $551,000 of severance paid in connection with headcount reductions related to cost savings initiatives; $2.9
million gain on the disposal of certain capital equipment; </FONT>$8.8 million of non-cash gain from interest rate swaps; $6.0 million
expense from debt restructuring and extinguishment as a result of our recent refinancing transaction; <FONT STYLE="color: black">and $2.0
million of amortization of deferred financing costs and loan discount related to our existing credit facilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>2021 Guidance Update</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RadNet amends its previously announced guidance
levels as follows:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">Original Guidance Range</TD><TD STYLE="padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0">Revised Guidance Range</P>
                                                                   <P STYLE="margin-top: 0; margin-bottom: 0">After Q1 Results</P></TD><TD STYLE="padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0">Revised Guidance Range</P>
                                                                   <P STYLE="margin-top: 0; margin-bottom: 0">After Q2 Results</P></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 24%; text-align: justify">Total Net Revenue</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 24%; text-align: justify">$1,250 - $1,300 million</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 23%; text-align: justify">$1,275 - $1,325 million</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 23%; text-align: justify">$1,300 - $1,350 million</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Adjusted EBITDA<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">$180 - $190 million</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">$187 - $197 million</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">$200 - $210 million</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Capital Expenditures<SUP>(a)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">$70 - $75 million</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">$72 - $77 million</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">$80 - $85 million</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Cash Interest Expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">$39 - $44 million</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">$35 - $40 million</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">$35 - $40 million</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Free Cash Flow <SUP>(b)(2)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">$60 - $70 million</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">$70 - $80 million</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">$75 - $85 million</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Net of proceeds from the sale of equipment, imaging centers and joint venture interests, and excludes
New Jersey Imaging Network capital expenditures.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Defined by the Company as Adjusted EBITDA<SUP>(1)</SUP> less Capital Expenditures and Cash Paid for Interest.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Dr. Berger highlighted,
&ldquo;Based upon the strong financial results in our first and second quarters and our confidence in projected performance for the remainder
of the year, we have increased guidance ranges for Revenue, Adjusted EBITDA</FONT><FONT STYLE="color: black"><SUP>(1)</SUP></FONT> <FONT STYLE="font-size: 10pt">and
Free Cash Flow</FONT> <FONT STYLE="color: black"><SUP>(2)</SUP></FONT><FONT STYLE="font-size: 10pt">. Additionally, we have raised our
Capital Expenditures level to reflect additional investments in growth opportunities we have identified in several of our core regional
markets.&rdquo; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Conference Call for Today</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Howard Berger, President and Chief Executive
Officer, and Mark Stolper, Executive Vice President and Chief Financial Officer, will host a conference call to discuss its second quarter
2021 results on Monday, August 9th, 2021 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Conference Call Details:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: Monday, August 9, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Time: 10:30 a.m. Eastern Time</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dial In-Number: 888-394-8218</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">International Dial-In Number: 646-828-8193</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">It is recommended that participants dial
in approximately 5 to 10 minutes prior to the start of the 10:30 a.m. call. There will also be simultaneous and archived webcasts available
at </FONT>http://public.viavid.com/index.php?id=146019 <FONT STYLE="font-size: 10pt">or http://www.radnet.com under the &ldquo;Investors&rdquo;
menu section and &ldquo;News Releases&rdquo; sub-menu of the website. An archived replay of the call will also be available and can be
accessed by dialing 844-512-2921 from the U.S., or 412-317-6671 for international callers, and using the passcode 3277272.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><B><I>Forward Looking Statements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify">This press release contains &ldquo;forward-looking
statements&rdquo; within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking
statements are expressions of our current beliefs, expectations and assumptions regarding the future of our business, future plans and
strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified
by words such as: &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;goal,&rdquo; &ldquo;seek,&rdquo; &ldquo;believe,&rdquo;
&ldquo;project,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;strategy,&rdquo; &ldquo;future,&rdquo; &ldquo;likely,&rdquo;
&ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;will&rdquo; and similar references to future periods. Forward-looking statements in this
press release include, among others, statements we make regarding response to and the expected future impacts of COVID-19, including statements
about our anticipated business results, balance sheet and liquidity and our future liquidity, burn rate and our continuing ability to
service or refinance our current indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify">Forward-looking statements are neither historical
facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties,
risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and
financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue
reliance on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to
differ materially from those indicated in the forward-looking statements include, among others, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the ongoing impact of the COVID-19 pandemic on
our business, suppliers, payors, customers, referral sources, partners, patients and employees, including (i) government&rsquo;s unprecedented
action regarding existing and potential restrictions and/or obligations related to citizen and business activity to contain the virus;
(ii) the consequences of an economic downturn resulting from the impacts of COVID-19 and the possibility of a global economic recession;
(iii) the impact of the volume of canceled or rescheduled procedures, whether as a result of government action or patient choice; (iv)
measures we are taking to respond to the COVID-19 pandemic, including changes to business practices; (v) the impact of government and
administrative regulation, guidance and appropriations; (vi) changes in our revenues due to declining patient procedure volumes, changes
in payor mix; (vii) potential increased expenses or workforce disruptions related to our employees that could lead to unavailability of
key personnel; (viii) workforce disruptions related to our key partners, suppliers, vendors and others we do business with; (ix) the impact
of return to work orders in certain states in which we operate; and (x) increased credit and collectability risks;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the availability and terms of capital to fund
our business;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to service our indebtedness, make
principal and interest payments as those payments become due and remain in compliance with applicable debt covenants, in addition to our
ability to refinance such indebtedness on acceptable terms;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">changes in general economic conditions nationally
and regionally in the markets in which we operate;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the availability and terms of capital to fund
the expansion of our business and improvements to our existing facilities;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to maintain our current credit rating
and the impact on our funding costs and competitive position if we do not do so;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">volatility in interest and exchange rates, or
credit markets;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the adequacy of our cash flow and earnings to
fund our current and future operations;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">changes in service mix, revenue mix and procedure
volumes; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">delays in receiving payments for services provided;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">increased bankruptcies among our partner physicians
or joint venture partners;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the impact of the political environment and related
developments on the current healthcare marketplace and on our business, including with respect to the future of the Affordable Care Act;
</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the extent to which the ongoing implementation
of healthcare reform, or changes in or new legislation, regulations or guidance, enforcement thereof by federal and state regulators or
related litigation result in a reduction in coverage or reimbursement rates for our services, or other material impacts to our business;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">closures or slowdowns and changes in labor costs
and labor difficulties, including stoppages affecting either our operations or our suppliers' abilities to deliver supplies needed in
our facilities;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the occurrence of hostilities, political instability
or catastrophic events; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the emergence or reemergence of and effects related
to future pandemics, epidemics and infectious diseases; and </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">noncompliance by us with any privacy or security
laws or any cybersecurity incident or other security breach by us or a third party involving the misappropriation, loss or other unauthorized
use or disclosure of confidential information.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any forward-looking statement contained in this
current report is based on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation
to publicly update any forward-looking statement, whether written or oral, that we may make from time to time, whether as a result of
changed circumstances, new information, future developments or otherwise, except as required by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulation G: GAAP and Non-GAAP Financial
Information</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This release contains certain financial information
not reported in accordance with GAAP. The Company uses both GAAP and non-GAAP metrics to measure its financial results. The Company believes
that, in addition to GAAP metrics, these non-GAAP metrics assist the Company in measuring its cash-based performance. The Company believes
this information is useful to investors and other interested parties because it removes unusual and nonrecurring charges that occur in
the affected period and provides a basis for measuring the Company's financial condition against other quarters. Such information should
not be considered as a substitute for any measures calculated in accordance with GAAP, and may not be comparable to other similarly titled
measures of other companies. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial
information prepared in accordance with GAAP. Reconciliation of this information to the most comparable GAAP measures is included in this
release in the tables which follow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>About RadNet, Inc.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">RadNet, Inc. is the leading national provider of freestanding, fixed-site
diagnostic imaging services and related information technology solutions (including artificial intelligence) in the United States based
on the number of locations and annual imaging revenue. RadNet has a network of 353 owned and/or operated outpatient imaging centers. RadNet's
markets include California, Maryland, Delaware, New Jersey, New York, Florida and Arizona. Together with affiliated radiologists, and
inclusive of full-time and per diem employees and technicians, RadNet has a total of approximately 8,300 employees. For more information,
visit http://www.radnet.com.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>CONTACTS: </I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>RadNet, Inc.</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Mark Stolper, 310-445-2800</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Executive Vice President and Chief Financial
Officer</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">RADNET, INC. AND SUBSIDIARIES</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CONDENSED CONSOLIDATED BALANCE SHEETS</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA)</P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2021</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2020</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">(unaudited)</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%; text-align: left">&nbsp;&nbsp;&nbsp;Cash and cash equivalents</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">140,852</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">102,018</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">157,328</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">129,585</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;Due from affiliates</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,290</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,836</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">30,449</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">32,985</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">334,919</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">270,424</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">PROPERTY, EQUIPMENT AND RIGHT-OF-USE ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">435,172</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">399,335</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;Operating lease right-of-use assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">593,574</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">483,661</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total property, equipment and right-of-use assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,028,746</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">882,996</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">OTHER ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;&nbsp;&nbsp;Goodwill</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">502,331</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">472,879</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;Other intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">51,783</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">52,393</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;Deferred financing costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,386</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,767</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;Investment in joint ventures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41,375</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,528</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;Deferred tax assets, net of current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,390</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,687</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;Deposits and other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">41,268</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">36,983</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,032,198</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,786,657</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: center">LIABILITIES AND EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT LIABILITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable, accrued expenses and other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">244,536</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">236,684</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;Due to affiliates</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,596</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,010</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,947</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39,257</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;Current finance lease liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,578</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;Current operating lease liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71,399</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65,794</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;&nbsp;Current portion of notes payable</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,789</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">39,791</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">381,267</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">398,114</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">LONG-TERM LIABILITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;Long-term finance lease liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">743</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;Long-term operating lease liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">567,674</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">463,096</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;Notes payable, net of current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">749,079</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">612,913</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;&nbsp;Other non-current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">34,899</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">53,488</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,732,919</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,528,354</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">RadNet, Inc. stockholders' equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; text-align: left">Common stock - $.0001 par value, 200,000,000 shares authorized; 52,678,030 and 51,640,537 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in-capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">324,954</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">307,788</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(22,227</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(24,051</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(105,668</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(117,999</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total RadNet, Inc.'s stockholders' equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">197,064</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">165,743</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Noncontrolling interests</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">102,215</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">92,560</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">299,279</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">258,303</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total liabilities and equity</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,032,198</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,786,657</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">RADNET, INC. AND SUBSIDIARIES</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA)</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(unaudited)</P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended June 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">REVENUE</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; width: 40%; font-weight: 400; font-style: normal; text-align: left">Service fee revenue</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">295,494</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">155,698</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">575,071</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">404,031</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Revenue under capitation arrangements</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">38,424</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">34,868</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">74,166</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">68,099</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 30pt; text-align: left">Total service revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">333,918</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">190,566</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">649,237</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">472,130</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Provider relief funding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,475</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,291</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,475</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">OPERATING EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt; text-align: left">Cost of operations, excluding depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">283,571</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">194,217</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">565,851</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">461,635</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,355</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,667</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,289</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt; text-align: left">(Gain) loss on sale and disposal of equipment and other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,567</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(569</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,874</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">202</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Severance costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">268</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">859</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">551</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,076</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: 400; font-style: normal; text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">306,283</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">215,862</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">610,195</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">506,202</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">INCOME (LOSS) FROM OPERATIONS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,678</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">179</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,597</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">OTHER INCOME AND EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,171</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,831</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,997</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,382</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Equity in earnings of joint ventures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,121</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(945</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,406</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,900</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-weight: 400; font-style: normal; text-align: left">Non-cash change in fair value of interest rate hedge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(35</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,843</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,280</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,843</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; font-weight: 400; font-style: normal; text-align: left">Debt restructuring and extinguishment expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,044</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,044</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other expenses (income)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,658</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(115</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,867</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(108</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 30pt; text-align: left; padding-bottom: 1pt">Total other (income) expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">16,717</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">13,614</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">16,222</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">23,217</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">INCOME (LOSS) BEFORE INCOME TAXES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,961</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13,435</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,111</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(31,814</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">(Provision for) benefit from income taxes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,874</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,475</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,249</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,856</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">NET INCOME (LOSS)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,087</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,960</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,862</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(22,958</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net income attributable to noncontrolling interests</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,214</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,634</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,531</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,994</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,873</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(10,594</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,331</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(26,952</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.05</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.21</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.24</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.53</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.05</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.21</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.23</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.53</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">WEIGHTED AVERAGE SHARES OUTSTANDING</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Basic</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">52,238,709</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">50,672,219</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">52,004,653</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">50,483,274</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">53,133,091</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">50,672,219</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">52,890,561</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">50,483,274</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CONDENSED CONSOLIDATED STATEMENTS OF CASHFLOWS</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(IN THOUSANDS)</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(unaudited)</P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 66%; text-align: left">Net income (loss)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">21,862</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(22,958</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Adjustments to reconcile net income&nbsp;&nbsp;(loss) to net cash provided by operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,667</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,289</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Amortization of operating lease assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,834</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,094</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Equity in earnings of joint ventures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,406</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,900</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Amortization deferred financing costs and loan discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,959</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,163</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">(Gain) loss on sale and disposal of equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,874</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">202</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Loss on extinguishment of debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,496</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Amortization of cash flow hedge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,845</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">892</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Non-cash change in fair value of interest rate hedge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,280</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,843</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,145</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,078</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Change in fair value of contingent consideration</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,292</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(97</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt; text-align: left">Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(28,156</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,018</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,963</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,884</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left">Other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,997</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,257</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Deferred taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,297</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,678</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left">Operating leases</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(36,564</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(30,182</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,147</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,384</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Accounts payable, accrued expenses and other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,765</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">27,690</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 30pt; text-align: left; padding-bottom: 1pt">Net cash provided by operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">58,701</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">131,465</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Purchase of imaging facilities and other acquisitions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(64,918</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,188</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Purchase of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(53,799</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(64,193</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Proceeds from sale of equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">779</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Equity contributions in existing joint ventures</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,441</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 30pt; text-align: left; padding-bottom: 1pt">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(119,658</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(67,602</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Principal payments on notes and leases payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,304</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,814</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Payments on Term Loan Debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(613,279</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(21,648</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Proceeds from issuance of new debt, net of issuing costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">716,369</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Proceeds from payment protection plan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,023</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Proceeds from revolving credit facility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">128,300</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,900</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Payments on revolving credit facility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(128,300</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(250,900</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Proceeds from issuance of common stock upon exercise of options</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">26</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 30pt; text-align: left; padding-bottom: 1pt">Net cash provided by (used in) financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">99,812</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(19,439</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">EFFECT OF EXCHANGE RATE CHANGES ON CASH</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(21</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">NET INCREASE IN CASH AND CASH EQUIVALENTS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,834</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,418</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">CASH AND CASH EQUIVALENTS, beginning of period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">102,018</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">40,165</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">CASH AND CASH EQUIVALENTS, end of period</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">140,852</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">84,583</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Cash paid during the period for interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">13,774</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">22,826</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.95pt 0pt 0; text-align: center; background-color: white"><B>RADNET,
INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.95pt 0pt 0; text-align: center; background-color: white"><B>RECONCILIATION
OF GAAP NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON SHAREHOLDERS TO ADJUSTED EBITDA<SUP>(1)</SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in; text-align: center; background-color: white"><B>(IN THOUSANDS)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in; text-align: center; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">Three Months Ended</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid">June 30,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 66%; text-align: left">Net Income (Loss) Attributable to RadNet, Inc. Common Shareholders</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">2,873</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(10,594</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Plus Interest Expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,171</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,831</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Plus Provision (Benefit) for Income Taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,874</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,475</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Plus Depreciation and Amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,355</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Plus Other Expenses (Income)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,658</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(115</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Plus Severance Costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">268</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">859</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Plus (Gain) on Sale of Equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,567</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(569</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Plus Debt Restructuring and Loss on Extinguishment Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,044</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Plus Non-cash Change in Fair Value of Interest Rate Hedge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(35</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,843</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Plus Other Adjustment to Joint Venture Investment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(565</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Plus Non Cash Employee Stock Compensation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,897</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,456</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 50pt; font-weight: 400; font-style: normal; padding-bottom: 2.5pt"><B>Adjusted EBITDA</B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400"><SUP>(1)</SUP></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">56,629</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">22,591</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">Six Months Ended</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid">June 30,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 66%; text-align: left">Net Income (Loss) Attributable to RadNet, Inc. Common Shareholders</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">12,331</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(26,952</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Plus Interest Expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,997</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,382</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Plus Provision (Benefit) for Income Taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,249</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,856</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Plus Depreciation and Amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,667</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,289</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Plus Other Expenses (Income)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,867</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(108</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Plus Severance Costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">551</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,076</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Plus (Gain) Loss on Sale of Equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,874</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">202</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Plus Debt Restructuring and Loss on Extinguishment Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,044</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Plus Non-cash Change in Fair Value of Interest Rate Hedge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,280</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,843</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Plus Other Adjustment to Joint Venture Investment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(565</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Plus Non Cash Employee Stock Compensation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,145</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,078</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 50pt; font-weight: 400; font-style: normal; padding-bottom: 2.5pt"><B>Adjusted EBITDA</B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400"><SUP>(1)</SUP></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">102,132</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">42,954</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in; text-align: center; background-color: white"><B></B></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in; text-align: center; background-color: white"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in; text-align: center; background-color: white"><B></B></P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">PAYOR CLASS BREAKDOWN</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 55%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Second Quarter</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">2021</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 39%; text-align: left">Commercial Insurance</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 13%; text-align: right">57.7%</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Medicare</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">21.4%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Capitation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">11.5%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Medicaid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">2.7%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Workers Compensation/Personal Injury</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">3.2%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">3.6%</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">100.0%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in; text-align: center; background-color: white"><B></B></P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">RADNET PAYMENTS BY MODALITY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Second Quarter</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Full Year</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Full Year</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Full Year</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 40%">MRI</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">36.7%</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">35.4%</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">35.8%</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">35.2%</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>CT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17.6%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17.6%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16.9%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16.5%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>PET/CT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.5%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.0%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.6%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.7%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>X-ray</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.2%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.3%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.1%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.4%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Ultrasound</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.6%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.3%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.4%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.2%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Mammography</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14.6%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.7%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.2%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.8%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Nuclear Medicine</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.1%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.0%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.0%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.1%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4.6%</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4.7%</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4.9%</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5.1%</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100.0%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100.0%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100.0%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100.0%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in; text-align: center; background-color: white"><B></B></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U><BR STYLE="clear: both">
</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Footnotes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>&nbsp;</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><SUP>(1)</SUP>
The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, each from continuing operations
and adjusted for losses or gains on the sale of equipment, other income or loss, debt extinguishments and non-cash equity compensation.
Adjusted EBITDA</FONT> includes equity earnings in unconsolidated operations and subtracts allocations of earnings to non-controlling
interests in subsidiaries<FONT STYLE="color: windowtext">, and is adjusted for non-cash or extraordinary and one-time events taken place
during the period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adjusted EBITDA is reconciled to its nearest comparable
GAAP financial measure. Adjusted EBITDA is a non-GAAP financial measure used as analytical indicator by RadNet management and the healthcare
industry to assess business performance, and is a measure of leverage capacity and ability to service debt. Adjusted EBITDA should not
be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation
or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data
presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a
measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented,
may not be comparable to other similarly titled measures of other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><SUP>(2)</SUP>
As noted above, the Company defines Free Cash Flow as </FONT>Adjusted EBITDA less total Capital Expenditures (whether completed with cash
or financed) and Cash Interest paid. <FONT STYLE="color: windowtext">Free Cash Flow is a non-GAAP financial measure. </FONT>The Company
uses Free Cash Flow because the Company believes it provides useful information for investors and management because it measures our capacity
to generate cash from our operating activities. Free Cash Flow does not represent total cash flow since it does not include the cash flows
generated by or used in financing activities. In addition, our definition of Free Cash Flow may differ from definitions used by other
companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Free Cash Flow should not be considered a measure
of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives
to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the
consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined
in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable
to other similarly titled measures of other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">RADNET, INC. AND SUBSIDIARIES</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">SCHEDULE OF ADJUSTED EARNINGS AND EARNINGS PER SHARE <FONT STYLE="font: normal 700 10pt Times New Roman, Times, Serif"><SUP>(3)</SUP></FONT></P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(IN THOUSANDS EXCEPT SHARE DATA)</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">June 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">June 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; width: 66%; font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC.
    COMMON STOCKHOLDERS</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD>$<TD STYLE="width: 13%; border-bottom: Black 2.5pt double; text-align: right">2,873</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 13%; border-bottom: Black 2.5pt double; text-align: right">(10,594</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Add COVID-19-related stock awards to front-line employees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,503</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Add non-cash revaluation of DeepHealth acquisiton shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,093</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Add non-cash impact of cash flow hedges (i)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,210</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,735</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Add severance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">268</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">859</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Add debt restructuring and extinguishment expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,044</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left">Total adjustments - loss (gain)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,118</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,594</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Subtract tax impact of Adjustments (ii)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,754</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,863</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD COLSPAN="2" STYLE="padding-left: 20pt">Tax effected impact of adjustments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">11,364</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">3,731</TD><TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL ADJUSTMENT TO NET INCOME ATTRIBUTABLE TO RADNET, INC.
    COMMON SHAREHOLDERS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,364</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,731</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">ADJUSTED NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">14,237</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(6,863</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">WEIGHTED AVERAGE SHARES OUTSTANDING</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">53,133,091</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,672,219</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">ADJUSTED DILUTED NET INCOME PER SHARE ATTRIBUTABLE TO RADNET,
    INC. COMMON STOCKHOLDERS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.27</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.14</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">(i) Impact is the combination
of (a) the gain in fair value of the hedges during the quarter of $35,000 in 2021 and loss of $3,843 in 2020 and (b) the amortization
of the accumulation of the changes in fair value out of Other Comprehensive Income that existed prior to the hedges becoming ineffective
of $1,245,000 in 2021 and $892,000 in 2020.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(ii) Tax effected using 24.83% blended federal and state effective tax rate for 2021 and 33.31% for 2020. </P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>radnet_ex9902.htm
<DESCRIPTION>TRANSCRIPT OF CONFERENCE CALL
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 99.2</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A"><B>C O R P O R A T E &nbsp;&nbsp;P A R T I
C I P A N T S</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper, </B><I>Executive Vice President
and Chief Financial Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger, </B><I>President and Chief
Executive Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A"><B>C O N F E R E N C E &nbsp;&nbsp;C A L L&nbsp;&nbsp;
P A R T I C I P A N T S</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut, </B><I>Jefferies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jonathan Ransom, </B><I>Raymond James</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mitra Ramgopal, </B><I>Sidoti &amp; Co., LLC</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A"><B>P R E S E N T A T I O N</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good day and welcome to the RadNet, Inc. Second
Quarter Financial Results Call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Today's conference is being recorded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At this time, I would like to turn the conference
over to Mr. Mark Stolper, Executive Vice President and Chief Financial Officer of RadNet, Inc. Please go ahead, sir.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you. Good morning, ladies and gentlemen,
and thank you for joining Dr. Howard Berger and me today to discuss RadNet's second quarter 2021 financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before we begin today, we'd like to remind everyone
of the Safe Harbor statement under the Private Securities Litigation Reform Act of 1995. This presentation contains forward-looking statements
within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning anticipated future
financial and operating performance, RadNet's ability to continue to grow the business by generating patient referrals and contracts with
radiology practices, recruiting and retaining technologists, receiving third-party reimbursement for diagnostic imaging services, successfully
integrating acquired operations, generating revenue and Adjusted EBITDA for the acquired operations as estimated, among others, are forward-looking
statements within the meaning of the Safe Harbor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Forward-looking statements are based on Management's
current preliminary expectations and are subject to risks and uncertainties which may cause RadNet's actual results to differ materially
from the statements contained herein. These risks and uncertainties include those risks set forth in RadNet's reports filed with the SEC
from time to time, including RadNet's Annual Report on Form 10-K for the year ended December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Undue reliance should not be placed on forward-looking
statements, especially guidance on future financial performance which speaks only as of the date it is made. RadNet undertakes no obligation
to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or
to reflect the occurrence of unanticipated events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With that, I'd like to turn the call over to Dr.
Berger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, Mark. Good morning, everyone, and thank
you for joining us today.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On today's call, Mark and I plan to provide you
with highlights from our second quarter 2021 results, give you more insight into factors which affected this performance and discuss our
future strategy. After our prepared remarks, we will open the call to your questions. I'd like to thank all of you for your interest in
our Company and for dedicating a portion of your day to participate in our conference call this morning.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before we start, I would like to say, on behalf
of myself and the entire team at RadNet, we hope all of you and your loved ones are healthy and staying safe. We are extremely grateful
for all of our stakeholders, including our employees, business partners, lenders and shareholders, and wish you all well during these
challenging times.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Let's begin. I'm extremely pleased with our performance
this quarter. Our financial and operating metrics in the second quarter demonstrate continuing strengthening and improvement in our business
that began in the third quarter of last year and as the result of a number of factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">First, the cost saving measures that we implemented
during the COVID-19 period in 2020, and further cost containment actions this year, have lowered our operating expenses and created efficiencies
within our regionally clustered centers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Second, our procedural volumes have substantially
recovered as many of the municipalities and states in which we operate have loosened COVID-19 restrictions. We are observing that patients
are returning to more regular office visits, utilizing health care with more normalcy. Obviously with the rise of the new Delta variant,
we remain vigilant and ready to take further protective actions should new restrictions or stay-at-home orders be implemented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lastly, investments we made last year and during
the first two quarters of this year, both with respect to capital expenditures and tuck-in acquisitions, are beginning to contribute to
our financial results. We discussed previously the extraordinary investments we made in upgrading our mammography systems during 2020
to 3-D digital mammography, or tomosynthesis. While we do not believe mammography volumes have fully recovered from their COVID-19 impact,
we are experiencing enhanced reimbursement from the volumes we are now performing on these newly upgraded 3-D systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, during the first quarter of this
year, we acquired 10 facilities within the New York metropolitan market, and we completed an additional five tuck-in acquisitions during
the second quarter in other parts of New York, New Jersey, and California. The newly acquired facilities had unique cost savings and consolidation
opportunities with existing RadNet facilities. We expect significant improvement from the results later in the year when we have completed
their integration processes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of all these factors, our results
during the second quarter were the best of any quarter in the Company&rsquo;s history. As compared with last year&rsquo;s second quarter,
which was impacted by COVID-19, revenue increased 75.2% and EBITDA more than 150%. I am particularly proud of the margin improvement we
were able to demonstrate, achieving an EBITDA margin of 17%, higher by 5.1% and 2.1% from the second quarters of 2020 and 2019 respectively.
The margin improvement is the result of both the return of our procedural volumes to more normalized levels as well as many of the cost
saving measures we have put in place, which has included consolidating underperforming sites and changing key operational processes, both
at the center level and within our Corporate Support departments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adjusted earnings were also very strong on the
quarter. We recognized adjusted net income per share during the quarter of $0.27. This is in contrast to an adjusted net loss per share
in last year&rsquo;s second quarter of $0.14. As a result of the strong performance in this year&rsquo;s first and second quarters, and
the confidence we are feeling for the remainder of the year, we have elected to, again, increase most of our key financial guidance levels
for 2021. Mark in his prepared remarks will review the increases we made to our revenue, EBITDA and free cash flow guidance, which were
outlined in our earnings press release this morning.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As many of you have seen, during the second quarter,
on April 26, we announced the completion of the refinancing of our term loan and revolving line of credit. Based upon current and anticipated
future leverage ratios, we expect to save up to $6 million annually in interest expense. Additionally, we no longer are subject to restrictive
maintenance covenants, with respect to our term loan, and have substantially more operating and financial flexibility under the new credit
agreement. This includes lowering our annual required amortization payments by over $30 million and adding over $110 million to our cash
balance, which will enable us to accelerate growth. The success of this refinancing can partly be attributed to our strong operating performance
and the effective deleveraging of our balance sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the end of this quarter, we had $633.3 million
in net debt, trailing 12-month EBITDA of $198.6 million, and a resulting leverage ratio of 3.19 times net debt to EBITDA. This is the
lowest leverage we have had in our Company&rsquo;s history.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pro forma for recent acquisition, this ratio was
even lower, which is indicative of our further expected deleveraging in the coming quarters. While we are committed to growing and expanding
our business, we will also continue to follow the methodical and disciplined approach to managing our financial leverage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lastly, before I hand the call back over to Mark,
I&rsquo;d like to provide an update as to where we stand with our efforts in artificial intelligence. During the second quarter, on April
19, we announced that our artificial intelligence subsidiary, DeepHealth, received FDA clearance for its AI mammography triage software,
Saige-Q. Saige-Q is a screening worklist prioritization tool that enables radiologists to more efficiently manage their mammography cases
with the use of artificial intelligence. DeepHealth&rsquo;s powerful new AI technology identifies suspicious screening exams that may
need prioritized attention, allowing radiologists to optimize their workflow for efficiency and accuracy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This technology is the first FDA-cleared triage
product that supports both 3-D and 2-D mammography images. With over 1.5 million mammography exams we are performing annually in our markets,
we are in the process of deploying this technology to our breast imagers nationwide. I am pleased to report that as of today, our Northeast
and Mid-Atlantic mammographers are now utilizing Saige-Q. We expect, by the end of the third quarter, our California breast imagers will
also be utilizing this technology. The early feedback we are receiving from our radiologists is excellent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While we are observing improved productivity,
most importantly we are providing our patients and payors with better accuracy, fewer patient callbacks, and the possibility of detecting
disease one to two years earlier than might otherwise be possible. We continue to evaluate further areas of artificial intelligence that
can both decrease our costs and drive new revenue streams through providing innovative cost-effective screening programs to large insurance
companies who are interested in new population health models to improve patient care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At this time, I'd like to turn the call back over
to Mark to discuss some of the highlights of our second quarter 2021 performance. When he is finished, I will make some closing remarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, Howard.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I&rsquo;m now going to briefly review our second
quarter 2021 performance and attempt to highlight what I believe to be some material items. I will also give some further explanation
of certain items in our financial statements as well as provide some insights into some of the metrics that drove our second quarter performance.
I will also provide an update to 2021 financial guidance levels, which were released in conjunction with our 2020 year-end results in
March, and which we amended in May upon releasing our first quarter financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In my discussion, I will use the term Adjusted
EBITDA, which is a non-GAAP financial measure. The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and
amortization, each from continuing operations, and excludes losses or gains on the disposal of equipment, other income or loss, loss on
debt extinguishments, and noncash equity compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adjusted EBITDA includes equity and earnings in
unconsolidated operations and subtracts allocations of earnings to non-controlling interests in subsidiaries and is adjusted for noncash
or extraordinary and one-time events taking place during the period. A full quantitative reconciliation of Adjusted EBITDA to net income
or loss attributable to RadNet, Inc. common shareholders is included in our earnings release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With that said, I'd now like to review our second
quarter 2021 results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the second quarter of 2021, RadNet reported
revenue of $333.9 million and Adjusted EBITDA of $56.6 million. Revenue increased $143.4 million, or 75.2%, and Adjusted EBITDA increased
$34 million, or 150.7%. The significantly improvement performance is the result of increased procedural volumes, cost reductions instituted
during the COVID-19 period, additional revenue from our migration to 3-D digital mammography, and the contribution from tuck-in acquisitions
we completed during the first two quarters of this year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adjusted earnings for the second quarter of 2021
were $14.2 million, or $0.27 per diluted share, as compared with adjusted net loss of $6.9 million, or negative $0.14 per diluted share,
for the same period in 2020. Unadjusted for one-time items, net income for the second quarter of 2021 was $2.9 million, or $0.05 per diluted
share. This compares to a net loss of $10.6 million, or negative $0.21 per diluted share, in the second quarter of last year. These per-share
values are based upon weighted average number of diluted shares outstanding of 53.1 million shares in the second quarter of 2021 and 50.7
million shares outstanding in the second quarter of 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Affecting net income in the second quarter of
2021 were certain noncash expenses and nonrecurring items including the following. Eight-point-nine million dollars of noncash employee
stock compensation expense, $268,000 of severance paid in connection with headcount reductions related to cost savings initiatives, $1.6
million gain on the disposal of certain capital equipment, $1.2 million of noncash loss from interest rate swaps, $6 million of expense
from debt restructuring and extinguishment as a result of our recent refinancing transaction, and $812,000 of amortization of deferred
financing costs and loan discounts related to our existing credit facilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the second quarter of 2021, as compared with
the prior-year second quarter, MRI volume increased 88.1%, CT volume increased 67.6%, and pet CT volume increased 28.8%. Overall volume,
taking into account routine imaging exams, inclusive of X-ray, ultrasound, mammography and all other exams, increased 92.7% over the prior-year
second quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On a same-center basis, including only those centers
which were part of RadNet for both the second quarters of 2021 and 2020, MRI volume increased 73%, CT volume increased 54.9%, and pet
CT volume increased 26.5%. Overall same-center volume, taking into account all routine imaging exams, increased 80.5% from the prior-year
same quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the second quarter of 2021 we performed 2,191,868
total procedures. The procedures were consistent with our multimodality approach, whereby 75.8% of all the work we did by volume was from
routine imaging. Our procedures in the second quarter of 2021 were as follows. Three-hundred twenty-one-thousand seven-hundred and seventy-nine
MRIs as compared with 171,047 MRIs in the second quarter of 2020, 197,375 CTs as compared with 117,730 CTs in the second quarter of 2020,
11,508 pet CTs as compared with 8,935 pet CTs in the second quarter of 2020, and 1,661,206 routine imaging exams compared with 1,137,281
of all these exams in the second quarter of 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Overall GAAP interest expense for the second quarter
of 2021 was $12.2 million. This compares with GAAP interest expense in the second quarter of last year of $10.8 million. Cash paid for
interest during the period, which excludes noncash deferred financing expense and accrued interest, was $5.5 million as compared with
$12.9 million in the second quarter of last year. The lower cash paid for interest in this year&rsquo;s second quarter is the result of
the timing of interest payments mainly due to our refinancing transaction in April.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With regards to our balance sheet, as of June
30, 2021, unadjusted for bond and term loan discounts, we had $633.3 million of net debt, which is our total debt at par value less our
cash balance. This compares with $608.6 million of net debt at June 30, 2020. Note that this debt balance includes New Jersey Imaging
Network&rsquo;s debt of approximately $49.1 million for which RadNet is neither a borrower nor a guarantor. As of June 30, 2021, we were
undrawn on our $195 million revolving line of credit and had a cash balance of $140.9 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At June 30, 2021, our accounts receivable balance
was $157.3 million, an increase of $27.2 million from year-end 2020. The increase in accounts receivable is mainly the result of the significant
increase in our procedural volumes and revenue this year relative to 2020 revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our days sales outstanding, or DSO, remains near
the lowest levels of our Company's history. Despite the increase in aggregate accounts receivable, our DSO was just 40.6 days at June
30, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Through June 30, 2021, we had total capital expenditures
net of asset dispositions and the sale of imaging center assets and joint venture interests of $48.3 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At this time, I'd like to update and revise our
2021 financial guidance levels, which we released in conjunction with our fourth quarter and year-end 2020 results and amended after reporting
our first quarter 2021 financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For revenue, our original guidance level was $1.250
billion to $1.300 billion. Our new guidance level, we&rsquo;ve increased both the low end and the top end of that guidance level by $50
million, to $1.3 billion to $1.350 billion of revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For Adjusted EBITDA, our original guidance level
was $180 million to $190 million. We&rsquo;ve increased both the low end and the high end of that range by $20 million, to $200 million
to $210 million of EBITDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For capital expenditures, our original guidance
range was $70 million to $75 million. We&rsquo;ve increased that to $80 million to $85 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><BR>
For cash interest expense, our original guidance level was $39 million to $44 million. We&rsquo;ve decreased our cash interest expense
guidance to $35 million to $40 million, which is reflective of the newer lower interest costs based upon our refinancing transaction in
April.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For free cash flow, our original guidance level
was $60 million to $70 million. We&rsquo;ve increased that to reflect our higher EBITDA projection, to $75 million to $85 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As just noted, we have increased our guidance
ranges for revenue, Adjusted EBITDA, and free cash flow. Additionally, we&rsquo;ve raised our capital expenditure level to reflect additional
investments in growth opportunities we&rsquo;ve identified in several of our core regional markets. Each quarter, we re-evaluate our actual
and projected performance against guidance levels. We will continue to update these levels as appropriate, throughout the remainder of
the year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I&rsquo;ll now take a few minutes to give you
an update on 2022 reimbursement and discuss what we know with regards to 2022 anticipated Medicare rates. As a reminder, Medicare represents
about 20% of our business mix.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to Medicare reimbursement, several
weeks ago, we received a matrix for proposed rates by CPT code, which is typically part of the physician fee schedule proposal that is
released about this time every year. We&rsquo;ve completed an initial analysis and compared those rates to 2021 rates. We volume-weighted
our analysis using expected 2022 procedural volumes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As you may recall, last year, CMS moved forward
with increased reimbursement for evaluation and management CPT codes, which favor certain physician specialties that regularly bill for
these services, particularly primary care doctors. CMS proposed doing so with budget neutrality, meaning that it proposed to reallocate
reimbursement from physicians who rarely bill for E&amp;M codes to physicians who regularly bill for these codes. As a result, radiology
and most other specialties are experiencing cuts in reimbursement during 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The cut that we are currently absorbing this year
would&rsquo;ve been higher if implemented as initially proposed last year, but Congressional action at the very end of last year partially
mitigated this cut.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this year&rsquo;s proposed rule governing 2022
reimbursement, Medicare appears to effectively be phasing in the remainder of the cut avoided last year. The cut proposed for 2022 results
from a decrease of the conversion factor in the Medicare fee schedule by about 3.8% along with additional decreases in technical and professional
RVUs of certain radiology CPT codes mostly focused on MRI and CT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our initial analysis of the proposal for next
year implies that RadNet, on roughly $1.3 billion in revenue, would face approximately a $13 million revenue hit in 2022 from its Medicare
business. Because the proposed cut and the conversion factor affects all physicians, not just radiologists, there are many lobbying groups
from the various medical specialties aggressively opposing the proposed cut, including radiology&rsquo;s two main lobbying forces, the
Association for Quality Imaging, or AQI, and the American College of Radiology, the ACR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At this time, our experts believe there is a possibility
that the final rule, to be released in November, will be less severe than the current proposal. Furthermore, it remains a possibility
that Congressional action this December could also mitigate these proposed cuts, like it did last year, particularly in light of a continuing
COVID-19 and Delta variant situation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November, during our third quarter financial
results call, we hope to have more to update you on about this matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I&rsquo;d now like to turn the call back to Dr.
Berger, who will make some closing remarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, Mark.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Today RadNet is more multifaceted than at any
other time in our history. We are growing our business in all of the seven states in which we operate, all of which have attractive demographics
and a multitude of local market opportunities. We are now partnering on both coasts with some of the largest and most prestigious hospital
and health systems in joint ventures that encompass approximately 25% of our facilities. We control our own IT infrastructure with our
own suite of eRAD products and services that we sell and license to other industry participants. And we are making significant investment
in the development of artificial intelligence, which we believe will have a transformative impact on our business and the diagnostic imaging
industry in general.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our multifaceted business is healthy and growing,
and we are exceeding the expectations that we originally set forth in our initial guidance levels, which we increased after the first
quarter&rsquo;s results and further increased today. Growth is coming from virtually all areas of our business, with patient volume returning
to more normal levels. And through implementing aggressive cost cutting and cost containment programs, our same-store growth and performance
model has returned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investments we made in 3-D digital mammography
technology are paying dividends with respect to increased reimbursement and improved patient care. New advances in equipment, contrast
materials, radioactive isotopes, post-processing digitalization software and many others will continue to drive new applications and patient
indications. Big pharma development for Alzheimer&rsquo;s and other diseases in the future bring the promise of greater utilization of
diagnostic imaging.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Most exciting to us is that our investments in
artificial intelligence have the potential for driving growth like we have never experienced. Using artificial intelligence to create
cost-effective screening programs for a variety of disease processes can uniquely impact population health. We are currently making inroads
with breast cancer and mammography, utilizing artificial intelligence, and we envision similar potential for prostate, lung and colon
cancer in the near future. We are evaluating further investments in artificial intelligence and look forward to updating you as they materialize.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><BR>
Furthermore, the refinancing transaction in April positions us with significantly more available financial resources as a result of the
over $110 million we were able to fund to our balance sheet, the lowering of our annual interest costs, and the substantial reduction
of acquired amortization. This liquidity in combination with the lowest financial leverage in our Company&rsquo;s history and our strong
free cash flow yield positions to us that are unique and give us the ability to execute on our growth opportunities, both organic and
external ones.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Strategic acquisitions will also continue to be
an important aspect of our growth. We routinely have a pipeline of acquisitions that we are evaluating and processing. Today, the arbitrage
between RadNet&rsquo;s enterprise value and the multiples for which we can purchase targets is more attractive than ever. As long as this
multiple arbitrage exists, we can continue to contribute to the equity value of RadNet through an acquisition strategy. We remain able
to acquire smaller operators in our core markets at three to five times EBITDA. While larger targets might cause us to stretch beyond
this evaluation level, they usually afford us more operating and cost synergies that, once achieved, serve to lower the acquisition multiples
into this range over time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will execute on these opportunities with this
level of discipline when targets are available and in instances when we have motivated sellers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In conclusion, we are excited and enthusiastic
about the opportunities that lie ahead for RadNet, and we look forward to updating you further in the upcoming quarters regarding our
progress.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operator, we are now ready for the question-and-answer
portion of the call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you. We can take our first question now
from Brian Tanquilut of Jefferies. Please go ahead.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hi, good morning guys. Congrats on a strong quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I guess, Howard, my first question for you. Obviously
a lot of discussion recently on the Delta variant and what it&rsquo;s doing to operations for health care. You&rsquo;re obviously in New
York and California, so the states that have probably been more aggressive with measures against the Delta. So just curious, what are
you seeing in terms of any impact on your referral flow or volume flow right now?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Also, you mentioned in your prepared remarks something
about preparing to&mdash;if lockdowns are mandated again, that you&rsquo;re preparing to make moves. Just curious, how are you guys strategizing
around this, and what would be different this time around?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good morning, Brian. Thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Well, firstly, I think we had seen, in the second
quarter, a robust return to the pre-COVID volumes, and there was anticipation, and still is, that the third quarter will continue this
recovery. What we are seeing is that the one area we&rsquo;re focused on very keenly, as far as the company strategy, meaning mammography
and breast cancer, seems to be a little slower to return.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We think this is because of two primary reasons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Number one, there are people that are still reluctant
to get elective procedures and visit health care facilities, given not only the concerns that they have about vaccinations and protective
measures, but also, as we now see the increase in the amount of COVID-positive results, there is that hesitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Secondly, and perhaps uniquely with mammography,
there have been a number of reports that women who are vaccinated do have a reaction, often in the auxiliary region on the arm that was
injected. There has been some recommendation that they wait two to three months after vaccination so that the potential inflammatory response
that&rsquo;s often seen in lymph nodes near and around the breast have a chance to subside. We believe that these are the primary reasons
why it might be a little slow to recover.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Returning to the other factors, we have now mandated
mask wearing for all of our employees and all patients in all of our centers across the United States. In addition to that, all of our
centers have been practicing social distancing, either in the waiting room itself, making certain that patients feel comfortable and are
separated, as well as having barriers at our reception desks. Often, with some of our unique eRAD methods for screening patients, patients
often wait outside and then are reminded when they are ready to come directly into the exam room for their procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Those are the recommendations that we have been
following now, and policies, for several months. If there is a continuation of this surge, we believe that most of the measures that we
put in place for safety measures and protective equipment simply can be followed, and I don&rsquo;t believe we should have a problem with
managing the health and safety of our patients that do choose to come. That is a risk, though, that, as the surge continues, it may influence
patients to hold off on elective procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also have to be mindful of the fact that, in
some of the states, fortunately, that we don&rsquo;t have a tremendous presence, the increase of the surge has also resulted in using
up the availability of hospital and ICU beds. If that were to occur, primarily in California and New Jersey, and in New York, then there
might be a further shutdown of elective procedures, which quite often have imaging associated with them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So far, through the months of September and early
August, we have not seen that impact noticeably in any of our regions, but we&rsquo;re monitoring it very closely.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, thanks for those comments, Howard.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I guess, Mark, shifting gears a little bit, margins
were really strong in the quarter, and I know you had cited that it&rsquo;s the carryover impact of moves that you made last year. But
as I think about the ability to sustain margins here going forward, and I know there&rsquo;s a balancing act between as utilization picks
back up or volumes pick back up, there&rsquo;s the capitation side of the business on one hand, and then obviously just the flow-through
to your fee-for-service business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">How are you thinking about margins going forward,
and your ability to drive incremental margin expansion?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sure. Well, if you look at our newly revised guidance
measures, we are assuming increased margins relative to where we were at the end of last year thinking about 2021&rsquo;s result. I think
that, given the changes that we made in our cost structure last year, the consolidation of a number of different centers, the implementation
of things like what Dr. Berger mentioned, virtual waiting rooms and other operating protocols to drive throughput in our facilities, some
advances in equipment, particularly some investments we made in digital 3-D mammography that is resulting in higher reimbursement per
scan on the mammography side, we have experienced a structural change in our margins and improvements of over 100 basis points relative
to where we were in 2019 and &rsquo;18. I&rsquo;m not going to compare it to last year, because it was such an extraordinary year with
the COVID impact. So we think that this is sustainable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Another reason for our improved results, our improvements
in investments we made in our revenue cycle, in terms of collecting more of our cash up front, getting better yields in general from our
AR. Our DSOs are at the lowest point in the Company&rsquo;s history at around 40 days. Our cash collections have been extremely strong,
which has also helped with deleveraging the balance sheet and providing us liquidity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We think that we can sustain the margins that
we&rsquo;ve been producing so far in the first and the second quarter. With the advent or with the implementation of AI, which Dr. Berger
also mentioned, on the mammography side, and hopefully if we get into other areas of AI, other screening tools and other modalities, that
can also structurally lower our costs of performing the radiology services but also drive new revenue streams that can significantly benefit
margins. At this point, we&rsquo;re very optimistic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Awesome. Last question for me. I think in Dr.
Berger&rsquo;s prepared remarks, he talked about investing more and expanding in AI into new areas. Anything you can share with us in
terms of your AI strategy beyond mammography? I know you&rsquo;ve talked about prostate and GI, but just anything you can share with us
in terms of AI strategy, where you can take that.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, Brian, thanks again.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><BR>
I think, as I have mentioned on previous closed calls, RadNet believes that imaging really is the gateway to population health. Within
that context, we believe that there should be aggressive and active efforts on screening tools, primarily for cancer and related to the
four major cancers that comprise about 80% of the diagnosed cancers on an annual basis, those being breast, prostate, lung and colon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Given the fact that in our particular business
where we do such a large volume of mammography already and we believe we are technologically and strategically positioned to do screening
for lung cancer, colon cancer and prostate cancer, we are exploring avenues that will ramp up the ability for us to perform these screening
tools on a mass scale, not only for the regions where RadNet owns centers, but the development of networks, perhaps across the country
and perhaps outside of the country, where we believe these tools will have the same benefits for population health.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While I can&rsquo;t comment on any specific avenues
at this moment, rest assured that we are aggressively looking at both internal as well as external ways for us to ramp up the development
of these tools, which we think will continue to have RadNet be the leader for this, not only in radiology, but also on a national scale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I can&rsquo;t emphasize enough how passionately
and strongly we feel about this, both as far as the benefits to society as a whole, in terms of health care and managing the costs, but
also the unique position that RadNet is in to both develop these internally, or perhaps continue acquisitions under our DeepHealth umbrella,
like we did last year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I think this will be more and more of an opportunity
for us to demonstrate RadNet&rsquo;s commitment to this as well as some of the unique tools, given that we also own our own IT infrastructure
and enormous amounts of data which are critical for the development of these tools to leverage on. We hope to be able to update you on
the progress towards these, perhaps as soon as our next quarter&rsquo;s earnings call or sooner if something materializes sufficient for
us to announce publicly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Awesome. Thanks again and congrats again. Thanks,
guys.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks, Brian.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks, Brian.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We can now take our next question from John Ransom
with Raymond James. Please go ahead.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jonathan Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hi, good morning. A couple things for me.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mark, your recent M&amp;A, is that having any
material effect on your outlook in the back half for the margins?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We&rsquo;ve been fairly active this year in M&amp;A.
In the first quarter, we did five small tuck-in transactions, and then in the second quarter here, we did 10 additional facility acquisitions.
As we&rsquo;ve said publicly, we&rsquo;re purely opportunistic in how we approach our acquisition strategy. We have a defined set of criteria
by which we look for targets and acquire businesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not go out and knock on any doors proactively;
we have a Business Development team that consists of one person. We only take, essentially, inbound calls, because we&rsquo;re looking
for motivated sellers in our markets where we can acquire them in the valuation range that we&rsquo;ve historically been successful in
affecting these transactions, which is in the three to five times range.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We&rsquo;ll stretch, at times, for highly strategic
acquisitions or acquisitions that are a little larger, but those generally come with greater synergies, and ultimately, we can average
down those multiples through time and better performance and through the synergies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A part of why we increased our guidance level
was from the increasing procedural volumes that we&rsquo;re seeing, both on a same-center basis as well as with new centers, including
those acquisitions, as well as the cost savings. Yes, those facility acquisitions will contribute to our financial profile for the portion
of the year that they&rsquo;re within the RadNet umbrella; those are going to have more impact next year, as we&rsquo;ll get the full
impact of all of those centers in next year&rsquo;s results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Also, it generally takes a quarter to two, depending
upon the size of the acquisition and the complexity, for us to integrate these acquired operations effectively into the RadNet way, for
lack of a better term. This includes getting them on our eRAD IT backbone, it includes operational protocols, clinical protocols, right-sizing
them, given our operational expertise. Yes, we will see some contribution, but it&rsquo;ll be more significant next year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jonathan Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we&rsquo;re thinking about kind of an early
bridge to next year, you&rsquo;ve got the $13 million headwind you mentioned. What&rsquo;s the approximate EBITDA contribution full year
next year from these acquisitions versus your partial year this year? How much is that is a good guide?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes. I mean, we haven&rsquo;t, John, disclosed
the EBITDA of any of these acquisitions publicly. But if you look at our cash flow statement for the first six months, there is a line
item that says purchase of imaging facilities and other acquisitions; it&rsquo;s about $65 million&hellip;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jonathan Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mm-hmm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&hellip;of enterprise value. If you assume, let&rsquo;s
say, that&rsquo;s done at a five times EBITDA, that can approximate give or take what the contribution of these acquired operations may
look like next year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jonathan Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Just to&hellip;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Or I wouldn&rsquo;t say next&mdash;on an annual
basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jonathan Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To show off my outstanding math skills, you&rsquo;re
buying about as much EBITDA as you&rsquo;re losing from Medicare. I know you&rsquo;ll get a partial year this year, but you&rsquo;re bridging
almost the full EBITDA gap from M&amp;A from Medicare.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, that&rsquo;s correct. Yes. I hadn&rsquo;t
thought about that, John, because that wasn&rsquo;t necessarily our intent in these acquisitions, but yes. We have other cost mitigants
from operational changes, maybe some consolidation of additional centers that we think will fully mitigate the cut next year. We&rsquo;re
hopeful, as I said in my prepared remarks, that the final rule will be a little bit less severe given COVID-19 and other variants that
are impacting all providers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, there&rsquo;s the opportunity, potentially,
that Congress rolls these cuts back, like they just last year, given the pressure that&rsquo;s being put on them. Because remember, when
they lower the conversion factor as is in this proposed rule, that&rsquo;s not just impacting radiology; that&rsquo;s impacting all medical
specialties. On this particular cut, it&rsquo;s not just the radiology lobbying groups that will be putting pressure on Congress; it&rsquo;s
essentially the entire AMA, maybe less the primary care physicians who are getting the increase in the E&amp;M codes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jonathan Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Got you. Then just a couple other clean-ups for
me. Your AI, you mentioned your AI strategy details. Is that going to make any difference in your per-read cost fees in the intermediate
term, or is that more of a longer-term efficiency tool?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good morning, John.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I think that&rsquo;s more of a long-term benefit.
The immediate benefits that we&rsquo;re realizing now are primarily improvements in the accuracy and efficiency with which our mammographers
are now able to read a mammogram. There are other developments in our pipeline or our pathway for mammography that we think will streamline
that process and ultimately allow our mammographers to read a greater volume of the mammograms than they are currently capable of. I believe
some of these new tools will probably start emerging next year, and when fully integrated with our IT platform, will, I believe, give
us some of these efficiencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These efficiencies, by and large, are not just
designed to reduce our professional costs, but really to allow the shortage of mammographers that exists on a national scale to handle
larger volumes of mammograms that we expect to be able to drive into our centers as a result of other compliance tools and contracting
that we want to do directly with the payors in facilitating greater efforts on their part through plan designs and other outreach programs
to get somewhere between the 50% to maybe as many as 100% of the women who are not getting annual mammography.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Part of this effort on artificial intelligence
is not only to raise quality, but to address the demand for really well-qualified breast imagers that remain a huge shortage on a national
scale, not just for RadNet and its radiology partners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jonathan Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks for that.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Then Mark, just your capitation contracts, I know
it&rsquo;s a smaller and smaller piece every year as you buy more fee-for-service. Are they generally helping as volumes trend a little
bit lower, or are they performing more or less in line?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes. I mean, capitation has remained fairly steady
in the 11% to 12% of our business mix, and that has been scaling along with the rest of the Company as we&rsquo;ve been growing the fee-for-service
business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jonathan Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We continue to think that there is more opportunity
within capitation, both for new contracts as well as potential increasing penetration of managed care, in California and other places,
that will drive more risk-taking, risk-based contracts, which we enjoy very much, as it helps to cover a lot of the fixed costs of our
facilities. It establishes relationships with many, many referring physicians who are obligated to send us these HMO patients that have
other fee-for-service business that can be sent to our centers because of that relationship.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Also, the financial benefits from capitation,
in terms of no DSOs, in terms of very low, if any, bad debt associated with these contracts, and other financial benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We think that this can continue to be a growth
engine for the Company. Obviously, as patients have returned to a more normal or regular way of utilizing health care and visiting their
primary care and other specialists that they go see, we have seen utilization increase, as expected, for these contracts, but they haven&rsquo;t
been increasing to any extraordinary levels.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A lot of people have asked me, John, do we feel
like we&rsquo;re benefiting in our business from a pent-up demand that might have existed during COVID. Our answer is no, we think it&rsquo;s
more&mdash;we may have seen a little of that in the third and the fourth quarter last year, but we see, it&rsquo;s really more towards
a normal use of health care services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The way we judge that is through our capitation
contracts where we see all of the exams that a patient population utilizes, because it&rsquo;s a closed patient population. We&rsquo;ve
seen increased utilization, but no unusual spikes, I would say.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jonathan Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Great. Are they all still in California, Mark,
these capitation contracts?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The vast majority of them are in California. Of
the roughly 1.9 million lives for which we&rsquo;re responsible on an exclusive basis under these capitated arrangements for providing
diagnostic imaging, a little over 1.7 of those exist in California. That&rsquo;s really due, John, to the structure of how managed care
contracts with large primary care physicians for patient care, here in California, where they&rsquo;re passing on the burden and the financial
responsibility for, essentially, non-hospital-based care to these large&hellip;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jonathan Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mm-hmm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&hellip;patient populations, to these larger medical
groups. Then we sub-capitate with these large medical groups, where they shift the utilization responsibility for diagnostic imaging to
us for a piece of the&hellip;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jonathan Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&hellip;per-member, per-month fee that they&rsquo;re
receiving from the various HMOs. It&rsquo;s very much&hellip;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jonathan Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, and it&hellip;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&hellip;a California phenomenon. There are other
states in the United States that do contract under this structure with HMOs. We see it a lot in Florida, you see it a lot in New Mexico,
in Nevada. That&rsquo;s catching on across the country where risk-taking, risk-sharing, population health is becoming more active.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do have a very significant contract in New
York with a division of EmblemHealth for New York metropolitan lives with their AdvantageCare physician group that has been a very successful
contract for both us and Emblem.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jonathan Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks so much, appreciate it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We can take our next question from Mitra Ramgopal
with Sidoti. Please go ahead.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mitra Ramgopal</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, hi, good morning, and thanks for taking the
questions. Just a couple for me.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I&rsquo;m just curious, on the increased Capex,
if maybe you can provide some color on some of the additional growth opportunities you&rsquo;re seeing there.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good morning, Mitra.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, most of that comes as a result of the acquisitions
we did in the first and second quarter. It&rsquo;s not at all uncommon for us that, in many of the acquisitions that we do, they have
deferred or delayed capital investment. Given the fact that we&rsquo;ve done through the year some 16 or 17 acquisitions, we do want to
invest in those sites, for example in new mammography systems to elevate or increase their mammography capabilities, particularly with
3-D mammography which we&rsquo;ve been able to demonstrate some very significant return on investment. That&rsquo;s the primary reason
that you&rsquo;re seeing the capital expenditure increase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mitra Ramgopal</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay, thanks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On the procedural volume increases, I think most
of it is a pent-up demand from COVID, but I was just wondering if you&rsquo;re maybe seeing some of that volume coming from more procedures
in the outpatient setting as United and Cigna start to increasingly seek to shift those procedures outside of the hospital. Maybe also,
just from a competitive landscape, COVID probably shook up the environment as it relates to some of your competitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, I believe some of the increased volume is
coming from that, Mitra. COVID seems to have really galvanized the health care insurers to really focus on this shift away from the more
expensive hospital-based imaging to the freestanding facilities. But some of this is slow to adopt, as it has been, but we are getting
more inbound calls from our insurance companies to help them facilitate those through plan design and other scheduling and authorization
tools that we&rsquo;re trying to ramp-up for them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I believe that there will be a component of the
increased volume that we see on a normal basis coming at the expense of some of the hospital systems. We also believe that as we implement
more and more of our artificial intelligence, we will be giving the insurers additional justification for making those changes. I think
there is a number of items that I think we&rsquo;ll be able to look back, perhaps at the end of this year, when we look at the contribution
to our fee-for-service business from the insurance companies and how that has changed. But the gut here, based on the calls that we&rsquo;re
getting and the participation that they&rsquo;re asking from us at this point, indicates that we should be quite a beneficiary of that
in our existing markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mitra Ramgopal</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay, thanks. Then final one, probably ahead of
(audio interference) on this, but as it relates to the (audio interference) reimbursement for 2022, assume it goes through (audio interference),
how comfortable you are as it relates to maybe being able to mitigate (phon) that impact, just from (audio interference) improving the
benefit (audio interference) but from additional costs measures that you (audio interference) the ability to implement?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Well, I think that there will be some measures
on the cost cutting side of it that we will always look to try to implement, whether or not those reimbursement cuts are affected or not.
But I think, given some of our unique capabilities where, as we&rsquo;ve demonstrated perhaps, consolidation opportunities, I believe
that will certainly help us mitigate that going into 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, we shouldn&rsquo;t dismiss the fact
that this reduction in reimbursement is not unique to RadNet and that this impact will be felt throughout the system. We expect that,
while it may take a little while, some of our competitors in the markets that we&rsquo;re in right now, and perhaps other markets that
we&rsquo;ll take a look at more aggressively, will feel the need to begin further serious consideration on consolidation. Perhaps as the
prior questioner was asking Mark, we believe that some of the mitigation may indeed come through the more opportunistic acquisitions that
we think will ramp-up, actually, in 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mitra Ramgopal</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay. Thanks again for taking the questions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, Mitra, take care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have no further questions at this time. I would
now like to hand the call back to Dr. Berger for any additional or closing remarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, Operator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Again, I would like to take this opportunity to
thank all of our shareholders for their continued support and the employees of RadNet for their dedication and hard work. Management will
continue its endeavor to be a market leader that provides great services with an appropriate return on investment for all stakeholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you for your time and I look forward to
our next call. Stay safe and good day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This concludes today's call. Thank you for your
participation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !C .8# 2(  A$! Q$!_\0
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M2*H484 #VI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#WZ-4_B)_R#[/_ *['_P!!K/\ !.AV&KZ9=2WT'FR1W+1J=Q&%VJ<<?4T
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HB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>rdnt-20210809.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kopo7xRiXgen8uEbXpMOaaM6aPty552aYkxvmR5fUl6Ly4pp/flsyYCy8WGoQIH -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:RDNT="http://radnet.com/20210809" elementFormDefault="qualified" targetNamespace="http://radnet.com/20210809">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://radnet.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="rdnt-20210809_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="rdnt-20210809_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>rdnt-20210809_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>rdnt-20210809_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://radnet.com/role/Cover" xlink:href="rdnt-20210809.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://radnet.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>radnet_i8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rdnt-20210809.xsd" xlink:type="simple"/>
    <context id="From2021-08-09to2021-08-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000790526</identifier>
        </entity>
        <period>
            <startDate>2021-08-09</startDate>
            <endDate>2021-08-09</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-08-09to2021-08-09">0000790526</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-08-09to2021-08-09">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2021-08-09to2021-08-09">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2021-08-09to2021-08-09">2021-08-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2021-08-09to2021-08-09">RadNet, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-08-09to2021-08-09">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2021-08-09to2021-08-09">001-33307</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-08-09to2021-08-09">13-3326724</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-08-09to2021-08-09">1510 Cotner Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2021-08-09to2021-08-09">Los Angeles</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-08-09to2021-08-09">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-08-09to2021-08-09">90025</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-08-09to2021-08-09">(310)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-08-09to2021-08-09">445-2800</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2021-08-09to2021-08-09">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2021-08-09to2021-08-09">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2021-08-09to2021-08-09">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2021-08-09to2021-08-09">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2021-08-09to2021-08-09">Common Stock, $.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-08-09to2021-08-09">RDNT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-08-09to2021-08-09">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-08-09to2021-08-09">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359253048216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 09, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  09,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">RadNet, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000790526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3326724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1510 Cotner Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Los Angeles<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">90025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(310)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">445-2800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.0001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RDNT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
M6:()4_GHU)+N    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ 6:()4YE<G",0!@  G"<  !,
M ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !9H@E3"8@-
M#"D$   A$   &               @($-"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ 6:()4Y^@&_"Q @  X@P   T
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;72YX;6Q02P4&      D "0 ^ @  P!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="radnet_i8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://radnet.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="radnet_i8k.htm">radnet_i8k.htm</File>
    <File>radnet_ex9901.htm</File>
    <File>radnet_ex9902.htm</File>
    <File>rdnt-20210809.xsd</File>
    <File>rdnt-20210809_lab.xml</File>
    <File>rdnt-20210809_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "radnet_i8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "radnet_i8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "rdnt-20210809_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rdnt-20210809_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "rdnt-20210809.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "RDNT",
   "nsuri": "http://radnet.com/20210809",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "radnet_i8k.htm",
      "contextRef": "From2021-08-09to2021-08-09",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://radnet.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "radnet_i8k.htm",
      "contextRef": "From2021-08-09to2021-08-09",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r9",
      "r11",
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r11": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r13": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r14": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r15": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r16": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001683168-21-003371-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001683168-21-003371-xbrl.zip
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M*[$,G@K\5%;JQ5JMKO *83,4@C.S,BPX#99WX664)IKGZ8Y!25FMU]6ZNN^
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MHA_S_K>SQ4^W#K^*(I7K:QHA6[2)*E)U70?[_DG.UWX)!LGL6%;G2/B8L&H
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MJ%)3R2-AKJG?\>@JK,__TG2YBM1(6K2O1I6KEJ5*8Q.7ZP=MG[P07%:D.J;
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MG LO^N$U: 18QB#8I^Z87&*X^,4.@E0+-07+I^3"\% 5J5;9D>FX2</#]+Q
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MS*&4VU=DJ9JLZKSU<OM9N^J^.;NV @_ +XH9MGGF_+;-?T65E'J&"[/=.",
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MY9%KN=_XPO -'GDA,AL&@%,C=.VRHEWK=<DR=E2JXJ6?)K\X?D!6+K3C8 F
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MH?.7Y$?@[]WG*7Z'/,7#3YJG^)VS!G]^_OKEKW_%7[Z_?O7C7_\O4$L#!!0
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M%*()*[8VA1L"/S@ %FTA%GA&F+G6!H1U?MDFO,P&^#NJ"L1#V+))!06?_-W
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MMVA 1MMLZ*J X "L 714:K28SWS.)$N\F\<"U.0A*9\'[Z$$U+N%I<=VFQE
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MT[7X)#:K3>*O%<Z(V/)?4$L#!!0    ( %FB"5.PCZ9&4P<  -!7   5
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M^U?MEO\!4$L! A0#%     @ 6:()4])#[4K:1   +\L" !$
M ( !     ')A9&YE=%]E>#DY,#$N:'1M4$L! A0#%     @ 6:()4VI=.6$]
M3@  [K$! !$              ( !"44  ')A9&YE=%]E>#DY,#(N:'1M4$L!
M A0#%     @ 6:()4\/+NV!)$P  -(\   X              ( !=9,  ')A
M9&YE=%]I.&LN:'1M4$L! A0#%     @ 6:()4Q1HW'<O P  Y@L  !$
M         ( !ZJ8  ')D;G0M,C R,3 X,#DN>'-D4$L! A0#%     @ 6:()
M4^(4P@+\"@  ?X8  !4              ( !2*H  ')D;G0M,C R,3 X,#E?
M;&%B+GAM;%!+ 0(4 Q0    ( %FB"5.PCZ9&4P<  -!7   5
M  "  7>U  !R9&YT+3(P,C$P.# Y7W!R92YX;6Q02P4&      8 !@!_ 0
&_;P

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
